EFFORTS Main Page Health Info Members Pages Links

New Meds, Trials, and Studies

MAC Lung Infection
Have you been recently/newly diagnosed with a MAC lung infection? MAC is the most common form of nontuberculous mycobacteria (NTM). NTM are bacteria commonly found in the environment. MAC can get inside your lungs when you breathe them in and can affect certain people more than others. Most people who come in contact with MAC do not develop an infection. However, some individuals are at a greater risk of developing an infection called MAC lung disease. MAC lung disease is a serious condition. If untreated, it can cause damage to the lungs.

A new study is looking for individuals with newly diagnosed MAC lung disease who may be interested in participating in a clinical study that is evaluating a drug for potential treatment of MAC lung infections and for the potential to improve symptoms of MAC lung infection including decreased respiratory discomfort and decreased fatigue.

Your participation in the study could potentially contribute to advancements in MAC lung disease research.

You can visit https://www.patientwing.com/ntmstudy-arise-encore-COPD for more information and to see if you may qualify. If you qualify to enroll, and decide to participate, you will be assigned to one of two studies investigating MAC lung disease.

Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) (AERIFY-2) dated Mar 23, 2022, sponsored by Sanofi

Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation (NOTUS) dated Feb 10, 2022, sponsored by Sanofi

🅰 Evaluation of the Safety and Efficacy of TLD in Patients With COPD (AIRFLOW–3) Nuvaira Lung Denervation System (Nuvaira System), Nuvaira’s Targeted Lung Denervation Therapy Shown to Lower Hospitalization Risk and see News “Nuvaira Hopes” dated September 11, 2019, sponsored by Nuvaira, Inc.

⚡ RejuvenAir® System Trial for COPD With Chronic Bronchitis (SPRAY–CB) sponsored by CSA Medical, see also RejuvenAir®

LEEP Losartan Effects on Emphysema Progression LEEP is a randomized clinical trial evaluating the effect of Losartan in helping people with Chronic Obstructive Pulmonary Disease (COPD) with emphysema – a disease of the lungs. We are looking for adults 40 years of age or older, current or former smokers, with COPD to join our study. The study is conducted in different states across the country.

🚬 Insight COPD Intervention Study In Overweight Patients with COPD We are trying to find out if a program proven to help people lose a modest amount of weight and increase their physical activity will improve COPD symptoms for those with a high BMI. To be in the study, you will need to have COPD, high BMI, history of smoking, shortness of breath, and be 40 years or older.

🚬 RETHINC REdefining Therapy IN early COPD The purpose of the RETHINC study is to determine whether symptomatic current and former smokers with normal lung function will benefit from the use of bronchodilator therapy currently used to treat patients who have Chronic Obstructive Pulmonary Disease (COPD).

🧪 Chronic Obstructive Pulmonary Disease Clinical Trials at UCSF 🧪 Trial list upated at least twice a week

Emphysema/COPD Research Registry [PA only] Have COPD, 40 and up, 10 year smoking history

Pulmonary Fibrosis Click the link to find many clinical trials avilable offered for Idiopathic Pulmonary Fibrosis, Cystic Fibrosis, Pulmonary Fibrosis by Clinicaltrials.gov
COPD Foundation Research Click Research on the main menu

📋 Find a Clinical Trial 📋 American Lung Association 📋

Clinical Trials GPS Find Trials by the US State
Center Watch List Find Trials across the World
ClinicalConnection Find US and International Trials
US NIH ClinicalTrials.gov Searched for trials for COPD, Chronic Obstructive Pulmonary Disease, Lung Disease, Lungs and more

COPD Resources and News for Living and Advocacy